Four-way distribution partnership provides quality, consistent rasH2 supply to India and China, better serving global customers
RENSSELAER, N.Y., March 22 (Bernama-GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd. (NSI) and Nomura Jimusho. Inc. (NJI) as sales agents and distributors of the rasH2 Mouse Carcinogenicity Test System in India and China, respectively. These distribution arrangements greatly improve rasH2 access for the burgeoning pharmaceutical industry in the Asia-Pacific region.The rasH2 transgenic mouse model is the only short-term (6-month) carcinogenicity test system that is both accepted by global regulatory authorities and readily available in commercial production. Invented by the Central Institute for Experimental Animals (CIEA), the rasH2 model is widely used as an alternative to the 2-year carcinogenicity bioassay, providing a faster, more accurate test system that better aligns with Russell & Burch's 3R tenets. Taconic and CLEA Japan, Inc (CLEA) have provided validated and consistent rasH2 mice for use in North America, Europe, and Asia since 2006, though access in India and China has been limited. As drug discovery and development activity increases in India and China, access to a carcinogenicity assay that is accepted by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as local authorities, is vital.
Under the new agreement, NSI serves as sales agent and distributor for India and NJI as sales agent and distributor for China. These distributors and sales agents greatly simplify the transaction process for users located in these countries. NSI and NJI will leverage CLEA and Taconic production colonies in Japan, Denmark, and the US to meet customer demand, facilitating investigator access. Taconic, CLEA, and CIEA closely monitor these colonies and perform regular functional studies using positive control compounds to assure performance critical for drug safety assessment. The arrangement also allows CLEA and Taconic to align production to meet global demand through improved visibility into rasH2 global use and needs.
“The rasH2 model has delivered on the promise of transgenic technology by demonstrating exceptional value in carcinogenicity assessment of new drugs, and the worldwide adoption of this system is a testament to its advantages in terms of speed, specificity, and total cost,” said Dr. Michael Seiler, vice president commercial products at Taconic.
"This historic collaboration ensures customers in every country have full access to the rasH2 carcinogenicity test system,” said Ryuta Nomura, CIEA chairman of the board and CEO. “This partnership will significantly increase the likelihood that all customers globally receive rasH2 as requested with minimal delay, enabling studies to be performed sooner and ultimately helping to get new life-saving medications on the market faster.”
To learn more about the rasH2 model, please call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.
No comments:
Post a Comment